#Ireland #Dublin #Alkermes #LYBALVI #ARISTADA

Alkermes' Spring 2025 Research Presentations

In a significant effort to advance mental health treatment, Alkermes plc has unveiled its research concerning psychiatric medications at various esteemed scientific gatherings this spring. This initiative lined up perfectly with Mental Health Awareness Month in May, underscoring the importance of supporting individuals grappling with mental health challenges.

Overview of the Conferences

Alkermes participated in key conferences, which included:

• - American Association of Psychiatric Pharmacists (AAPP) Annual Meeting: April 27-30, Salt Lake City
• - Neuroscience Education Institute (NEI) Spring Congress: May 8-10, Philadelphia
• - Professional Society for Health Economics and Outcomes Research (ISPOR) Annual Conference: May 13-16, Montreal
• - American Psychiatric Association (APA): May 17-21, Los Angeles
• - American Society of Clinical Psychopharmacology (ASCP) Annual Meeting: May 27-30, Scottsdale
• - Psych Congress Elevate: May 28-31, Las Vegas

Craig Hopkinson, M.D., the Chief Medical Officer at Alkermes, expressed pride in the company’s involvement at these key events, saying, "Alkermes is honored to present at these notable scientific meetings, sharing our research and insights with thought leaders and healthcare providers from across the field of psychiatry."

Key Research Highlights

During these conferences, Alkermes presented vital research findings focused on its flagship products, LYBALVI® and ARISTADA®.

LYBALVI® (olanzapine and samidorphan)

1. Lipid and Glycemic Profiles Analysis:
A novel investigation showcased findings from a long-term safety study involving lipid and glycemic effects over four years in adult patients treated with LYBALVI. This was a critical assessment that could influence treatment paradigms for adults living with schizophrenia and bipolar I disorder.

2. Tolerability and Durability Studies:
Research also included safety and tolerability evaluations, emphasizing the prolonged effectiveness of LYBALVI in diverse patient subgroups over time.

3. Negative Symptoms of Schizophrenia:
Alkermes revealed post hoc findings regarding the impact of LYBALVI on negative symptoms of schizophrenia during acute and long-term treatment stages.

4. Real-World Assessments:
The presentations also covered significant real-world data, highlighting healthcare resource utilization in patients who have initiated treatment with LYBALVI.

ARISTADA® (aripiprazole lauroxil)

1. Efficacy and Safety Evaluations:
The study at these conferences examined the efficacy and safety of ARISTADA given every two months, particularly considering varying levels of schizophrenia severity in adults. This kind of targeted analysis is crucial for tailoring treatments in psychiatric settings.
2. Treatment Patterns:
Another notable research presentation showcased treatment patterns and healthcare resource utilization among patients on ARISTADA versus other treatments, enriching the dialogue on prescribing practices in the mental health sector.

A Commitment to Patient Care

Dr. Hopkinson emphasized Alkermes' unwavering commitment to enhancing patient care in neuro-psychiatry. "We welcome the opportunity to contribute to these important conversations and advocate for innovative solutions that improve the quality of life for individuals facing these challenging mental health disorders."

Alkermes continues to invest in its research and development in order to better understand and treat mental health conditions, a commitment that remains as critical today as ever. The insights shared at these conferences will play a vital role in shaping future treatment approaches.

Overall, Alkermes’ robust data presentations reflect a significant step forward in the efficacy of psychiatric medications and underline the company’s ongoing dedication to advancing mental health care.